GET SET Study (A191901): a clinical trial for guiding endocrine therapy success




## What is GET SET?

GET SET stands for Guiding Endocrine Therapy Success through Empowerment and Technology.

The GET SET Study is a research study for women like you who take medicine to help keep breast cancer from coming back. The medicines are endocrine therapies, and include Tamoxifen or Arimidex.

Women belong to 1 of 4 groups in the study. Each group offers basic education about endocrine therapy. Some groups will get extra support programs, like daily text message reminders and telephone counseling sessions.



## Why was GET SET created?

Endocrine therapy can reduce the risk of breast cancer coming back by half. But it's common for women to have trouble taking these medicines on a regular basis. The GET SET Study helps you stick to taking your endocrine therapy medicines, for as long as you need to.

Most women learn about this medicine from their healthcare team when it's prescribed. But some women say they need extra support to help them stay on track with their medicine.

The GET SET Study will test different kinds of extra support programs. We want to learn which programs help women take their endocrine therapy medicine.

Patients like you helped create the support programs. But we don't know which parts of the program are most helpful to women taking these medicines.

## Who can join the GET SET Study?

You may be able to take part if:

- You found out you have hormone receptor positive breast cancer in the last 18 months
- You're currently taking (or you've been recently prescribed) an endocrine therapy medicine
- You've finished surgery, radiation and chemotherapy treatment for your breast cancer
- You want extra support to help you stay on track with taking your endocrine therapy medicine

Talk to your doctor to find out more about the study and to see if you're eligible. Or visit our website to learn more!

## www.getsetstudy.org

This work is supported through a National Cancer Institute (NCI) award (RO1CA237357-01).